Elekta announced it has received approval to CE Mark its Integrity™ R1.1 treatment control system in the European Union. Integrity R1.1 combines a three-tier safety system with continuously variable dose rate (CVDR) and interdigitation capabilities for Elekta’s MLCi2™ multi-leaf collimator (MLC). Integrity supports a complete range of delivery techniques – such as Intensity Modulated Radiation Therapy (IMRT), Volumetric Modulated Arc Therapy (VMAT) and stereotactic applications – while ensuring maximum patient safety.
Incorporating three tiers of safety, Integrity has undergone rigorous tests in eight international centers, which demonstrated safe reductions in treatment times of as high as 30 percent. The approval of the CE Marking for Integrity enables European medical centers to realize these treatment speed and safety benefits when Elekta begins delivery of the control systems.
“We depend on Integrity to ensure that the linac does what it is supposed to do,” says Prof. Frank Lohr, Vice Chairman of University Medical Center Mannheim (UMC, Germany). “Our data, using Integrity on a variety of plans, shows that VMAT plans are significantly accelerated and treatment delivery is considerably smoother than with the previous control system. On average, Integrity has reduced treatment times by 20 to 30 percent.”
UMC is one of eight centers that participated in testing Integrity and has used the Integrity R1.0 control system for a year on two Elekta treatment machines that are dedicated almost exclusively to delivering IMRT and VMAT. Efficiently delivering these complex techniques has been facilitated by CVDR and MLC interdigitation, both enabled via Integrity.
“Because 60 percent of all our patients received IMRT – with 70 percent of that group receiving VMAT – the ability of Integrity to support MLC interdigitation and CVDR becomes even more critical, as they greatly enhance treatment delivery speed,” Prof. Lohr observes. “Integrity has shown to be a good, reliable product – it does what it should and does it well, enabling us to provide the benefits of IMRT and VMAT to patients who will benefit most from these modulated therapies. Integrity also will help us fully exploit future innovations.”
Read more at: http://www.elekta.com/healthcare_international_press_release_20071300.php.
